Cargando…
Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury
Mild traumatic brain injury (TBI) and concussion can have serious consequences that develop over time with unpredictable levels of recovery. Millions of concussions occur yearly, and a substantial number result in lingering symptoms, loss of productivity, and lower quality of life. The diagnosis may...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650880/ https://www.ncbi.nlm.nih.gov/pubmed/37958226 http://dx.doi.org/10.3390/diagnostics13213330 |
_version_ | 1785135883126571008 |
---|---|
author | Rauchman, Steven H. Pinkhasov, Aaron Gulkarov, Shelly Placantonakis, Dimitris G. De Leon, Joshua Reiss, Allison B. |
author_facet | Rauchman, Steven H. Pinkhasov, Aaron Gulkarov, Shelly Placantonakis, Dimitris G. De Leon, Joshua Reiss, Allison B. |
author_sort | Rauchman, Steven H. |
collection | PubMed |
description | Mild traumatic brain injury (TBI) and concussion can have serious consequences that develop over time with unpredictable levels of recovery. Millions of concussions occur yearly, and a substantial number result in lingering symptoms, loss of productivity, and lower quality of life. The diagnosis may not be made for multiple reasons, including due to patient hesitancy to undergo neuroimaging and inability of imaging to detect minimal damage. Biomarkers could fill this gap, but the time needed to send blood to a laboratory for analysis made this impractical until point-of-care measurement became available. A handheld blood test is now on the market for diagnosis of concussion based on the specific blood biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl terminal hydrolase L1 (UCH-L1). This paper discusses rapid blood biomarker assessment for mild TBI and its implications in improving prediction of TBI course, avoiding repeated head trauma, and its potential role in assessing new therapeutic options. Although we focus on the Abbott i-STAT TBI plasma test because it is the first to be FDA-cleared, our discussion applies to any comparable test systems that may become available in the future. The difficulties in changing emergency department protocols to include new technology are addressed. |
format | Online Article Text |
id | pubmed-10650880 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-106508802023-10-28 Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury Rauchman, Steven H. Pinkhasov, Aaron Gulkarov, Shelly Placantonakis, Dimitris G. De Leon, Joshua Reiss, Allison B. Diagnostics (Basel) Review Mild traumatic brain injury (TBI) and concussion can have serious consequences that develop over time with unpredictable levels of recovery. Millions of concussions occur yearly, and a substantial number result in lingering symptoms, loss of productivity, and lower quality of life. The diagnosis may not be made for multiple reasons, including due to patient hesitancy to undergo neuroimaging and inability of imaging to detect minimal damage. Biomarkers could fill this gap, but the time needed to send blood to a laboratory for analysis made this impractical until point-of-care measurement became available. A handheld blood test is now on the market for diagnosis of concussion based on the specific blood biomarkers glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl terminal hydrolase L1 (UCH-L1). This paper discusses rapid blood biomarker assessment for mild TBI and its implications in improving prediction of TBI course, avoiding repeated head trauma, and its potential role in assessing new therapeutic options. Although we focus on the Abbott i-STAT TBI plasma test because it is the first to be FDA-cleared, our discussion applies to any comparable test systems that may become available in the future. The difficulties in changing emergency department protocols to include new technology are addressed. MDPI 2023-10-28 /pmc/articles/PMC10650880/ /pubmed/37958226 http://dx.doi.org/10.3390/diagnostics13213330 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Rauchman, Steven H. Pinkhasov, Aaron Gulkarov, Shelly Placantonakis, Dimitris G. De Leon, Joshua Reiss, Allison B. Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury |
title | Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury |
title_full | Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury |
title_fullStr | Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury |
title_full_unstemmed | Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury |
title_short | Maximizing the Clinical Value of Blood-Based Biomarkers for Mild Traumatic Brain Injury |
title_sort | maximizing the clinical value of blood-based biomarkers for mild traumatic brain injury |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10650880/ https://www.ncbi.nlm.nih.gov/pubmed/37958226 http://dx.doi.org/10.3390/diagnostics13213330 |
work_keys_str_mv | AT rauchmanstevenh maximizingtheclinicalvalueofbloodbasedbiomarkersformildtraumaticbraininjury AT pinkhasovaaron maximizingtheclinicalvalueofbloodbasedbiomarkersformildtraumaticbraininjury AT gulkarovshelly maximizingtheclinicalvalueofbloodbasedbiomarkersformildtraumaticbraininjury AT placantonakisdimitrisg maximizingtheclinicalvalueofbloodbasedbiomarkersformildtraumaticbraininjury AT deleonjoshua maximizingtheclinicalvalueofbloodbasedbiomarkersformildtraumaticbraininjury AT reissallisonb maximizingtheclinicalvalueofbloodbasedbiomarkersformildtraumaticbraininjury |